Grant ID | RP240311 |
Awarded On | February 21, 2024 |
Title | Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging |
Program | Academic Research |
Award Mechanism | Individual Investigator |
Institution/Organization | The University of Texas M.D. Anderson Cancer Center |
Principal Investigator/Program Director | Richard Bouchard |
Cancer Sites | Ovary |
Contracted Amount | $1,049,859 |
Lay Summary |
Despite significant advances in the treatment of ovarian cancer (OC), patients with recurrent metastatic malignancies still have poor outcomes, and most of these patients will experience disease relapse. For advanced or metastatic OC disease, platinum-based chemotherapy remains the primary backbone for systemic treatment. Unfortunately, platinum-resistant OC occur in about 20% of patients after first-line platinum-based chemotherapy. To address this problem, mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate (ADC) comprising a folate receptor alpha (FRa)-binding antibody, was recently granted FDA approval for patients suffering from platinum-resistant disease with high FRa expre... |